| # |
Company Name
|
Industry Name
|
Latest Price (Rs.)
|
Price Change
Rs (%) |
Market Cap
|
Net Sales
(Rs. Cr.) |
Latest EPS
(Rs.) |
Net Profit
Margin % |
Latest
P/E |
Latest
P/BV |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Reddys Labs. | Pharmaceuticals& Drugs | 1,166.7 |
-8.3 (-0.71%) |
Mid Cap | 33,700 | 38.6 | 11.44 | 30.4 | 2.6 | |
| Cipla | Pharmaceuticals& Drugs | 1,463 |
-12.05 (-0.82%) |
Mid Cap | 28,163 | 41.7 | 13.45 | 35.4 | 3.4 | |
| Lupin | Pharmaceuticals& Drugs | 2,373 |
-18.5 (-0.77%) |
Mid Cap | 27,958 | 116.6 | 18.82 | 20.5 | 4.9 | |
| Zydus Lifesciences | Pharmaceuticals& Drugs | 1,109.2 |
2.95 (0.27%) |
Mid Cap | 27,148 | 50.5 | 16.54 | 21.9 | 4.2 | |
| Glenmark Pharma. | Pharmaceuticals& Drugs | 2,270.8 |
-28.2 (-1.23%) |
Mid Cap | 13,322 | 63.7 | 9.67 | 36.1 | 5.9 | |
| Aurobindo Pharma | Pharmaceuticals& Drugs | 1,643.8 |
54.3 (3.42%) |
Mid Cap | 11,172 | 45.1 | 20.59 | 35.3 | 3.9 | |
| Mankind Pharma | Pharmaceuticals& Drugs | 2,437.3 |
6.35 (0.26%) |
Mid Cap | 10,421 | 52.8 | 19.97 | 46 | 5.9 | |
| Alkem Laboratories | Pharmaceuticals& Drugs | 5,583 |
-25.45 (-0.45%) |
Mid Cap | 9,664 | 182.8 | 22.7 | 30.7 | 4.8 | |
| Ipca Laboratories | Pharmaceuticals& Drugs | 1,723 |
-10.45 (-0.6%) |
Mid Cap | 7,289 | 44.6 | 16.38 | 38.8 | 5.5 | |
| Abbott India | Pharmaceuticals& Drugs | 27,675.1 |
-210.75 (-0.76%) |
Mid Cap | 6,929 | 730.4 | 22.25 | 38.2 | 12.5 | |
| Laurus Labs | Pharmaceuticals& Drugs | 1,849.7 |
13.7 (0.75%) |
Mid Cap | 6,813 | 20.2 | 12.82 | 90.7 | 17.6 | |
| Ajanta Pharma | Pharmaceuticals& Drugs | 3,483.6 |
11.55 (0.33%) |
Mid Cap | 5,453 | 90.8 | 19.33 | 38.2 | 8.9 | |
| Glaxosmithkline Phar | Pharmaceuticals& Drugs | 2,615 |
35.4 (1.37%) |
Mid Cap | 3,822 | 63.1 | 25.36 | 40.9 | 17.3 | |
| Biocon | Pharmaceuticals& Drugs | 427 |
-10.55 (-2.41%) |
Mid Cap | 2,346 | 0.6 | 5.85 | 729.8 | 2.6 | |
| Anthem Biosciences | Pharmaceuticals& Drugs | 836.4 |
10.95 (1.33%) |
Mid Cap | 2,089 | 11.1 | 30.95 | 74.5 | 14.3 |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: